




Using BiP inducer X to target the unfolded protein response for T-cell Acute Lymphoblastic Leukaemia treatment

(or: T-ALL's Achilles' Heel- Disrupting the UPR for Therapeutic Gain)


Shani Mistriel Zerbib, Nira Twaik, Leonor Daniel and Michael Berger

The Lautenberg Center for Immunology and Cancer Research, IMRIC, Hebrew University of Jerusalem


T-ALL development in the thymus




UPR activation supports leukemic survival, making it a targetable vulnerability



T-ALL depends on UPR to survive




T-ALL relies on an active UPR: IRE1 supports survival, PERK aids stress response, and ATF6 fine-tunes proliferation





Is UPR Disruption a Therapeutic Strategy for T-ALL?

To explore UPR as a therapeutic target, we first examine how T-ALL depends on this pathway for survival

Sfn2 loss of function...





XBP1 loss disrupts UPR balance, making T-ALL more aggressive




Targeting UPR homeostasis via ATF6 selectively impairs T-ALL progression

The Disruptor: BIX




BIX (BiP Inducer X) upregulates BiP/GRP78, reducing ER stress and apoptosis (Hirota et al., 2011)




Cracking the Mechanism


BIX Influences T-ALL Independently of BiP Overexpression



BIX Targets UPR Functionality in T-ALL, Not in A431 Cells




BIX increases nuclear ATF6 degradation, altering UPR signaling



BIX amplifies ATF6 degradation thus impairing T-ALL survival

Preclinical Findings: BIX Disrupts T-ALL Progression



Conclusions

BIX selectively impairs T-ALL by tipping the UPR balance could be a novel therapeutic strategy

Think you can disrupt the UPR better than BIX? Prove it!

